Zobrazeno 1 - 10
of 22
pro vyhledávání: '"L Menéndez Naranjo"'
Publikováno v:
Nutrición Hospitalaria, Vol 19, Pp 18-18 (2004)
Externí odkaz:
https://doaj.org/article/f022ecb5ec1945379e4386d23f9b7881
Autor:
M Díaz Ramón, A. Espuny Miró, A Ruiz Gómez, L Menéndez Naranjo, A Laorden Carrasco, Já Cano Molina, M Sáez Garrido
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Over the last few years there have been remarkable advances in chronic hepatitis C virus (HCV) drug development, and the goals of most new regimens have been increasing sustained viral response rates (SVR), improving tolerab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f837cc8d3e1211371e44916e6fa2e57c
https://doi.org/10.1136/ejhpharm-2020-eahpconf.350
https://doi.org/10.1136/ejhpharm-2020-eahpconf.350
Autor:
C Ramirez Roig, JI García Soler, L Menéndez Naranjo, Já Cano Molina, M Valderrey Pulido, M Díaz Ramón, E González Lozano, A Laorden Carrasco, S Vicente Sánchez, V Arocas Casañ
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Ocrelizumab is the first drug approved in Europe for the treatment of primary progressive multiple sclerosis (PPMS). It is an anti-CD20 monoclonal antibody whose use has also been authorised in early forms of PPMS and recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75631819c79169cba6b5d81c959c9823
https://doi.org/10.1136/ejhpharm-2020-eahpconf.207
https://doi.org/10.1136/ejhpharm-2020-eahpconf.207
Autor:
S Vicente Sánchez, MJ Sánchez Garre, L Menéndez Naranjo, M Almanchel Rivadeneyra, A Tomás Luiz, M Valderrey Pulido
Publikováno v:
Drug information and pharmacotherapy.
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment, particularly in allowing interferon free therapy. HIV coinfection is common, with genotypes 1 and 4 being t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::889a273b31369a6316683b40ac19d80d
https://doi.org/10.1136/ejhpharm-2017-000640.266
https://doi.org/10.1136/ejhpharm-2017-000640.266
Autor:
MA de la Rubia Nieto, M Valderrey Pulido, S Vicente Sánchez, L Menéndez Naranjo, JI García Soler, Mdm Ruiz Jimenez
Publikováno v:
Drug information and pharmacotherapy.
Background The new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients. Purpose To analyse the use of dolutegravir/abacavir/lamivudine co-formulated (DTG/ABC/3TC) 50 mg/6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a7dbcde0f1ffaf542d428b9a363ead9
https://doi.org/10.1136/ejhpharm-2017-000640.269
https://doi.org/10.1136/ejhpharm-2017-000640.269
Autor:
M Almanchel Rivadeneyra, L Menéndez Naranjo, A Mancebo González, A Tomás Luiz, JJ Fernández Ávila
Publikováno v:
Drug information and pharmacotherapy.
Background Darunavir/cobicistat (DRV/COBI) is an antiviral medicine recently approved in our hospital for simplifying the posology of patients previously treated with darunavir 800 mg and ritonavir 100 mg, in combination with other medicines. Purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7620a60718171065b8affaf63756371b
https://doi.org/10.1136/ejhpharm-2017-000640.323
https://doi.org/10.1136/ejhpharm-2017-000640.323
Publikováno v:
Farmacia Hospitalaria. 35:158-160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fe28c39512ac6d7d5a62e9c3928f8fb
https://doi.org/10.1016/j.farma.2010.09.002
https://doi.org/10.1016/j.farma.2010.09.002
Autor:
MJ Sánchez Garre, A Mancebo González, A De la Rubia Nieto, L Menéndez Naranjo, M Almanchel Rivadeneyra, MC Muñoz Contreras
Publikováno v:
European Journal of Hospital Pharmacy. 23:A126.2-A127
Background Dolutegravir has been marketed in Spain since last year. It is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV infected adults and adolescents >12 years of age. Due to its recent approval, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aa5fbc20cfa067b09da4c8cedcbc7ed
https://doi.org/10.1136/ejhpharm-2016-000875.287
https://doi.org/10.1136/ejhpharm-2016-000875.287
Autor:
MJ Sánchez Garre, S Vicente Sánchez, A De la Rubia Nieto, MC Muñoz Contreras, L Menéndez Naranjo, M Almanchel Rivadeneyra
Publikováno v:
European Journal of Hospital Pharmacy. 23:A14.2-A15
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment. Interferon free combinations such as sofosbuvir (SOF) plus daclatasvir (DAC) have become available this yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68f809ed7c78ec425f9132adbf9b843d
https://doi.org/10.1136/ejhpharm-2016-000875.33
https://doi.org/10.1136/ejhpharm-2016-000875.33
Autor:
M Almanchel Rivadeneyra, S Vicente Sánchez, MJ Sánchez Garre, L Menéndez Naranjo, MC Muños Contreras, ADe la Rubio Nieto
Publikováno v:
European Journal of Hospital Pharmacy. 23:A12.2-A13
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment, particularly to allow interferon free therapy. It is important to decide which treatment is best suited to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f93309bfdc38d5b7273733b4a0312e2
https://doi.org/10.1136/ejhpharm-2016-000875.28
https://doi.org/10.1136/ejhpharm-2016-000875.28